Protein

Insights on the Potato Protein Global Market to 2027 - Shifting Consumer Preference Toward Vegan Dietary Patterns Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 12, 2023
Health, Environment, Sustainability, Fitness & Nutrition, Agriculture, Natural Resources, Animal, Livestock, COVID-19, Absorption, Health, Starch, International Union of Biochemistry and Molecular Biology, Digestion, Protein, Water, Growth, Metabolism, Snack, Centrifugation, Infant, Food

Potato protein is the dry by-product collected during the generation and separation of potato starch.

Key Points: 
  • Potato protein is the dry by-product collected during the generation and separation of potato starch.
  • It is a rich source of digestible protein and amino acid profile and is extracted from potato juice through precipitation and centrifugation.
  • Potato protein is commonly available in concentrated, isolated and hydrolyzed variants and is widely used as an alternative to animal-sourced proteins.
  • With the shifting consumer preference toward vegan dietary patterns, there is a rising demand for potato protein as an effective source of plant-based protein.

Outlook on the RNA Analysis Global Market to 2028 - Featuring Illumina, Bio-Rad Laboratories, Eurofins Scientific and Merck Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023
Biotechnology, Genetics, Health, Classification, Genome, Gene expression, RNA, Phenotype, Toxicity, RNA transfection, DNA, Personalized medicine, Molecular biology, Orthornavirae, Microarray, Biomarker, Collection, Transcriptome, Research, Vaccine, Gene, Drug development, Protein, RNA-Seq, Application, MicroRNA, Drug discovery, Cancer, CVD, Data analysis, Real-time, Real, Toxicology, Healthcare

The Global RNA Analysis Market size is expected to reach $28 billion by 2028, rising at a market growth of 15.6% CAGR during the forecast period.

Key Points: 
  • The Global RNA Analysis Market size is expected to reach $28 billion by 2028, rising at a market growth of 15.6% CAGR during the forecast period.
  • The method used to produce RNA in a lab setting from a DNA template is known as in vitro transcription.
  • For use in procedures like in vitro translation, the investigation of RNA viruses, and RNA: protein interaction investigations, RNA is produced from DNA templates using in vitro transcription devices.
  • For use in RNA analysis research, single-stranded RNA probes, microgram amounts of specified RNA transcripts, and antisense RNA are all prepared using riboprobe systems.

Global Protein Therapeutics Market Report 2022 to 2028 - Increase in the Cases of Cancer Across the World Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023
Health, Other Health, Disease, Cell, Blood, Degenerative disease, Metastasis, Coagulopathy, Neoplasm, Health, Plasma, Genetic disorder, Protein, Water, Genetic, Genetic engineering, Growth, Patient, Prevalence, Sugar, Salt, Enzyme, Antibody, Infection, Pharmaceutical industry, Vaccine, Cancer

The Global Protein Therapeutics Market size is expected to reach $490.2 billion by 2028, rising at a market growth of 6.9% CAGR during the forecast period.

Key Points: 
  • The Global Protein Therapeutics Market size is expected to reach $490.2 billion by 2028, rising at a market growth of 6.9% CAGR during the forecast period.
  • They can also increase the supply of a helpful protein, which helps lessen the effects of chemotherapy or sickness.
  • One of the major factors that are driving the growth of the protein therapeutics market is the expansion in the prevalence of various types of cancer all over the world.
  • A major challenge in the growth of the protein therapeutics market is the high cost of protein therapies.

Adimab Provides Year-End Update on 2022 Partnership Activities

Retrieved on: 
Tuesday, January 10, 2023
Stem Cells, Biotechnology, Pharmaceutical, General Health, Health, Infectious Diseases, Health Technology, Genetics, G protein-coupled receptor, Control, Ion, Complex, Monoclonal antibody, Cytokine, Bispecific monoclonal antibody, Alnylam Pharmaceuticals, Regeneron Pharmaceuticals, HC, TCR, Biogen, Partnership, Protein, International Association of Students in Agricultural and Related Sciences, Engineering, Stanford University, FC, Antibody, CD3, Immunoglobulin G, Top of the Form (quiz show), Bristol Myers Squibb, DEM, Pharmaceutical industry, Fine chemical, Vaccine, Vertex

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it entered into partnership agreements with 11 new companies in 2022.

Key Points: 
  • Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it entered into partnership agreements with 11 new companies in 2022.
  • In addition, Adimab expanded its collaborations with Biogen, Biotheus, Bristol Myers Squibb, Invivyd, Link Immunotherapeutics, Regeneron, Surface Oncology, and Werewolf.
  • In 2022, Adimab and its partners initiated discovery on 57 new therapeutic programs, bringing the total number of royalty-bearing programs commenced to over 475.
  • “Our growth in the number of therapeutic programs continues to be remarkable,” said Guy Van Meter, Chief Business Officer of Adimab.

Global Market for Bio-based Materials 2023 to 2033: Players Include NatureWorks, Total Corbion, Danimer Scientific and Novamont - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023
Science, Other Science, Biotechnology, Environment, Health, Recycling, Chemicals, Plastics, Manufacturing, AMSilk, Polyethylene terephthalate, Positive economics, Solvent, Borealis, OF, Danimer Scientific, MFC, Polyethylene 2,5-furandicarboxylate, NatureWorks, Polymer, Biofuel, DN5, ECH, Mitsubishi Chemical Corporation, MEG, Hydroxymethyl group, Fermentation, HMF, DuPont, BASF, Biomass, Renewable Polyethylene, MPG, Acrylate, Plastic, Biopolymer, PBS, BY, Polylactic acid, Ecovative Design, Alginic acid, Succinic acid, Breeding, PHA, Protein, Lactic acid, MycoWorks, Wool, Naphtha, Biorefinery, Coal, Fine chemical, Thermoplastic, Petrochemical, Polyethylene, Lignin, Dibutyl sebacate, Alkyd, Polyhydroxyalkanoates, Cellulose, Isosorbide, Itaconic anhydride, Arkema, Epichlorohydrin, Polysaccharide, Cathay, Levulinic acid

The Global Market for Bio-based Materials to 2033 presents a complete picture of the current market and future outlooks, covering bio-based chemicals and feedstocks, materials, polymers, bio-plastics, bio-fuels and bio-based paints and coatings.

Key Points: 
  • The Global Market for Bio-based Materials to 2033 presents a complete picture of the current market and future outlooks, covering bio-based chemicals and feedstocks, materials, polymers, bio-plastics, bio-fuels and bio-based paints and coatings.
  • Materials from biomass sources include bulk chemicals, platform chemicals, solvents, polymers, and biocomposites.
  • The many processes to convert biomass components to value-added products and fuels can be classified broadly as biochemical or thermochemical.
  • In depth market analysis of bio-based chemical feedstocks, biopolymers, bioplastics, natural fibers and lignin, biofuels and bio-based coatings and paints.

SlimFast Re-energizes Consumers' 2023 New Year's Resolutions with Nationwide "Resolution Reboot" this January

Retrieved on: 
Thursday, January 12, 2023
Vanilla, DIY, New Year, Fatigue, Intermittency, Punch (drink), Comment, Protein, Intermittent fasting, SlimFast, Fasting, Exercise, Financial services, Fast food, Keto

DOWNERS GROVE, Ill., Jan. 12, 2023 /PRNewswire/ -- With more than 80 percent of Americans1 abandoning their New Year's resolutions by February, SlimFast, part of the Glanbia Performance Nutrition portfolio and a leading global weight management brand for over 45 years, is setting out to support Americans with their resolution goals through its "Resolution Reboot." The brand's "Resolution Reboot" kicks off today with tips, resources and incentives to avoid resolution burnout. In an effort to give consumers a deliciously doable boost to achieve – and maintain – their goals, SlimFast will give away $20,000 worth of motivational prize packages ranging from fitness class memberships, one-on-one consultations with a registered dietitian, spa treatments and products from SlimFast's robust portfolio.

Key Points: 
  • The brand's "Resolution Reboot" kicks off today with tips, resources and incentives to avoid resolution burnout.
  • "Our 'Resolution Reboot' is intended to help consumers reset their intentions during the new year and beyond."
  • "As an industry leader SlimFast has helped millions of Americans manage their weight," continues Lombard.
  • "We are committed to offering a selection of products that support people no matter where they are in their journey.

Cambrian BioPharma Unveils New Pipeline Company - Isterian Biotech

Retrieved on: 
Thursday, January 12, 2023
Aston, Cell, Ageing, Tissue, Longevity, ECM, Extracellular matrix, Lung, Protein, Aston University, Drug discovery, Idiopathic pulmonary fibrosis, Drug design, Fibrosis, Enzyme, Doctor of Philosophy, IPF, Pharmaceutical industry, TG2

NEW YORK, Jan. 12, 2023 /PRNewswire/ -- Cambrian BioPharma, a multi-asset longevity biotech, today unveils its latest pipeline company, Isterian Biotech. This preclinical start-up is working towards the development of first-in-class small molecule inhibitors of transglutaminase 2 (TG2), one of the major crosslinking enzymes in the human body, which becomes more active during aging resulting in fibrotic diseases.

Key Points: 
  • NEW YORK, Jan. 12, 2023 /PRNewswire/ -- Cambrian BioPharma , a multi-asset longevity biotech, today unveils its latest pipeline company, Isterian Biotech .
  • "Using this state-of-the-art approach to drug discovery combined with an impressive team gives us great confidence in the future of this novel company."
  • In 2019, Aston University partnered with Cambrian to form Isterian Biotech with a mission to develop safe and effective TG2 inhibitors to treat Idiopathic pulmonary fibrosis (IPF), a devastating fibrotic disease of the lung.
  • "Isterian and its work to reduce fibrosis are a perfect fit alongside the other pipeline companies our team has announced in 2022."

Evozyne Creates AI Model with NVIDIA for Novel Protein Design, Expected to Accelerate Drug Development

Retrieved on: 
Thursday, January 12, 2023
Paragon, Machine learning, AI, Gene editing, Drug development, NVIDIA, Biology, Phenylalanine hydroxylase, Protein, Conference, Imagination, Health, Therapy, Engineering, PAH, Research, Deep learning, Nature, Genetic disorder, Medical device, Vaccine, Antibiotics, Fine chemical

CHICAGO, Jan. 12, 2023 /PRNewswire/ -- Evozyne today revealed a breakthrough AI model, developed in collaboration with NVIDIA, that the pharmaceutical industry can use to design therapeutic proteins.

Key Points: 
  • New AI model, co-developed by Evozyne and NVIDIA, can create novel therapeutic proteins for a new era of drug development
    CHICAGO, Jan. 12, 2023 /PRNewswire/ -- Evozyne today revealed a breakthrough AI model, developed in collaboration with NVIDIA, that the pharmaceutical industry can use to design therapeutic proteins.
  • Evozyne began a collaboration with NVIDIA in 2022 to develop a new deep learning model that can learn the rules of protein function and use these rules to design new proteins with improved functions.
  • The model, known as the Protein Transformer Variational AutoEncoder (ProT-VAE), is built on NVIDIA BioNeMo , a framework for efficiently training and deploying large language models for biology.
  • Using the Evozyne ProT-VAE model and NVIDIA BioNeMo framework, the team designed new synthetic PAH variants predicted to have "supernatural" function.

Research commenced with Keio University to discover drugs using "Chemicals Informatics"

Retrieved on: 
Thursday, January 12, 2023
Biology, Disease, Cell, Quality, Quality of life, Materials informatics, CI, Knowledge, Research, AI, Drug development, Protein, Drug discovery, MI, Cancer, Clinical trial, Enzyme, D, Pharmaceutical industry, Fine chemical, Pharmacy

Small molecule drugs are mainstream drugs in the modern world, and in recent years, expectations for their use have increased, with the development of drugs such as molecular-targeted drugs that inhibit the action of proteins, which cause cancer(2).

Key Points: 
  • Small molecule drugs are mainstream drugs in the modern world, and in recent years, expectations for their use have increased, with the development of drugs such as molecular-targeted drugs that inhibit the action of proteins, which cause cancer(2).
  • MI is expected to solve these challenges by using information science techniques, such as AI, to improve the efficiency of compound and material development.
  • In the Research, Keio University Faculty of Pharmacy, Department of Pharmaceutical Sciences will use Hitachi High-Tech Solutions' CI to study the development of new drugs to act as selective inhibitors that will block enzymes that produce active sulfur molecules.
  • (2) Molecular-targeted drugs: A therapeutic agent designed to act only on specific molecules that cause disease.

Avalon GloboCare Announces Issuance of Key U.S. Patent for Multiple Novel QTY-Code Modified Cytokine and Chemokine Protein Receptor Molecules

Retrieved on: 
Tuesday, January 17, 2023
Avalon, Cancer, Education, Patent, COVID-19, Solubility, 1836 U.S. Patent Office fire, Intellectual property, MIT, Protein, CAR, Massachusetts Institute of Technology, Therapy, Vaccine

FREEHOLD, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technologies and therapeutics and laboratory testing provider, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.

Key Points: 
  • FREEHOLD, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technologies and therapeutics and laboratory testing provider, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.
  • 11,555,060, titled “QTY Fc Fusion Water Soluble Receptor Proteins.” The issued claims cover the composition of matter and methodology for multiple novel QTY-code modified cytokine and chemokine protein receptor molecules.
  • The patent was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT).
  • “We are pleased to be granted this key patent by the USPTO which expands our intellectual property portfolio,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare.